WeightWatchers will file for bankruptcy in the coming weeks after finally negotiating a deal on its $1.6 billion of debt.

With the price of eggs skyrocketing, many CPG companies are scrambling for alternatives and while plant-based options have ...

Sequence, a telehealth platform providing access to GLP-1 weight-loss medications, was purchased to integrate prescription weight-loss solutions into WeightWatchers' existing programmes ...

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...

However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—commonly used in treating type 2 diabetes and obesity—may offer new promise in treating AUD.